WO2019054808A3 - Utilisation de peptides en tant qu'agent thérapeutique contre des maladies auto-immunes et des maladies osseuses - Google Patents

Utilisation de peptides en tant qu'agent thérapeutique contre des maladies auto-immunes et des maladies osseuses Download PDF

Info

Publication number
WO2019054808A3
WO2019054808A3 PCT/KR2018/010873 KR2018010873W WO2019054808A3 WO 2019054808 A3 WO2019054808 A3 WO 2019054808A3 KR 2018010873 W KR2018010873 W KR 2018010873W WO 2019054808 A3 WO2019054808 A3 WO 2019054808A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
diseases
therapeutic agent
autoimmune diseases
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2018/010873
Other languages
English (en)
Korean (ko)
Other versions
WO2019054808A2 (fr
Inventor
조대호
김경은
김면수
박선영
정희영
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kine Sciences Co Ltd
Original Assignee
Bio Pep Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN202311703381.5A priority Critical patent/CN117777239A/zh
Priority to CA3075607A priority patent/CA3075607C/fr
Priority to EP18857312.5A priority patent/EP3682892A4/fr
Priority to JP2020515231A priority patent/JP7122018B2/ja
Priority to CN201880059598.8A priority patent/CN111148525B/zh
Priority to US16/646,069 priority patent/US11629169B2/en
Priority to AU2018332486A priority patent/AU2018332486B2/en
Priority claimed from KR1020180110473A external-priority patent/KR102166930B1/ko
Application filed by Bio Pep Co Ltd filed Critical Bio Pep Co Ltd
Priority claimed from KR1020180110480A external-priority patent/KR102166929B1/ko
Publication of WO2019054808A2 publication Critical patent/WO2019054808A2/fr
Publication of WO2019054808A3 publication Critical patent/WO2019054808A3/fr
Anticipated expiration legal-status Critical
Priority to US18/174,730 priority patent/US20230234985A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne l'utilisation de peptides en tant qu'agent thérapeutique. Il a été confirmé que les peptides selon la présente invention inhibent significativement l'activité des lymphocytes T et la différenciation des lymphocytes T auxiliaires 17 (lymphocytes Th17), qui sont associés à des maladies auto-immunes, et présentent des effets remarquables en matière de traitement et d'amélioration de l'arthrite chez un modèle animal de l'arthrite. Par conséquent, les peptides peuvent être utilisés en tant que principe actif dans des agents thérapeutiques contre diverses maladies auto-immunes telles que des maladies osseuses, des maladies inflammatoires ou la polyarthrite rhumatoïde.
PCT/KR2018/010873 2017-09-15 2018-09-14 Utilisation de peptides en tant qu'agent thérapeutique contre des maladies auto-immunes et des maladies osseuses Ceased WO2019054808A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2018332486A AU2018332486B2 (en) 2017-09-15 2018-09-14 Use of peptides as therapeutic agent for autoimmune diseases and bone diseases
EP18857312.5A EP3682892A4 (fr) 2017-09-15 2018-09-14 Utilisation de peptides en tant qu'agent thérapeutique contre des maladies auto-immunes et des maladies osseuses
JP2020515231A JP7122018B2 (ja) 2017-09-15 2018-09-14 自己免疫疾患および骨疾患の治療剤としてのペプチドの用途
CN201880059598.8A CN111148525B (zh) 2017-09-15 2018-09-14 作为自身免疫疾病及骨病治疗剂的肽的用途
US16/646,069 US11629169B2 (en) 2017-09-15 2018-09-14 Use of peptides as therapeutic agent for autoimmune diseases and bone diseases
CN202311703381.5A CN117777239A (zh) 2017-09-15 2018-09-14 作为自身免疫疾病及骨病治疗剂的肽的用途
CA3075607A CA3075607C (fr) 2017-09-15 2018-09-14 Utilisation de peptides en tant qu’agent thérapeutique contre des maladies auto-immunes et des maladies osseuses
US18/174,730 US20230234985A1 (en) 2017-09-15 2023-02-27 Use of peptides as therapeutic agent for autoimmune diseases and bone diseases

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
KR10-2017-0118949 2017-09-15
KR20170118949 2017-09-15
KR20170118947 2017-09-15
KR10-2017-0118947 2017-09-15
KR1020180110480A KR102166929B1 (ko) 2017-09-15 2018-09-14 자가면역질환 치료제로서의 펩타이드의 용도
KR10-2018-0110480 2018-09-14
KR1020180110473A KR102166930B1 (ko) 2017-09-15 2018-09-14 골질환 치료제로서의 펩타이드의 용도
KR10-2018-0110473 2018-09-14

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/646,069 A-371-Of-International US11629169B2 (en) 2017-09-15 2018-09-14 Use of peptides as therapeutic agent for autoimmune diseases and bone diseases
US18/174,730 Continuation US20230234985A1 (en) 2017-09-15 2023-02-27 Use of peptides as therapeutic agent for autoimmune diseases and bone diseases

Publications (2)

Publication Number Publication Date
WO2019054808A2 WO2019054808A2 (fr) 2019-03-21
WO2019054808A3 true WO2019054808A3 (fr) 2019-05-31

Family

ID=65723663

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/010873 Ceased WO2019054808A2 (fr) 2017-09-15 2018-09-14 Utilisation de peptides en tant qu'agent thérapeutique contre des maladies auto-immunes et des maladies osseuses

Country Status (1)

Country Link
WO (1) WO2019054808A2 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110143993A1 (en) * 2009-12-15 2011-06-16 The Brigham And Women's Hospital, Inc. Endothelial basement membrane targeting peptide ligands
KR20140005110A (ko) * 2012-07-03 2014-01-14 일양약품주식회사 신규한 펩타이드 및 이의 용도
US20140087997A1 (en) * 2011-05-11 2014-03-27 Technion Research & Development Foundtion Limited Anti-microbial peptides and uses of same
WO2016204841A1 (fr) * 2015-06-17 2016-12-22 Avon Products, Inc. Peptides et leur utilisation dans le traitement de la peau
WO2017155233A1 (fr) * 2016-03-09 2017-09-14 주식회사 바이오펩 Peptide de prévention ou de traitement de maladies inflammatoires et son utilisation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110143993A1 (en) * 2009-12-15 2011-06-16 The Brigham And Women's Hospital, Inc. Endothelial basement membrane targeting peptide ligands
US20140087997A1 (en) * 2011-05-11 2014-03-27 Technion Research & Development Foundtion Limited Anti-microbial peptides and uses of same
KR20140005110A (ko) * 2012-07-03 2014-01-14 일양약품주식회사 신규한 펩타이드 및 이의 용도
WO2016204841A1 (fr) * 2015-06-17 2016-12-22 Avon Products, Inc. Peptides et leur utilisation dans le traitement de la peau
WO2017155233A1 (fr) * 2016-03-09 2017-09-14 주식회사 바이오펩 Peptide de prévention ou de traitement de maladies inflammatoires et son utilisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3682892A4 *

Also Published As

Publication number Publication date
WO2019054808A2 (fr) 2019-03-21

Similar Documents

Publication Publication Date Title
EP4596041A3 (fr) Agonistes du récepteur farnésoïde x et leursutilisations
CA3148745A1 (fr) Inhibiteurs de kras g12d
EP4501932A3 (fr) Inhibiteurs de kras g12c
WO2018022664A8 (fr) Compositions de neuromodulation et méthodes thérapeutiques associées pour le traitement de maladies inflammatoires et auto-immunes
MY196330A (en) Diacylglycerol Acyltransferase 2 Inhibitors
EP4488265A3 (fr) Compositions thérapeutiques, combinaisons et procédés d'utilisation
SG10201914118SA (en) Methods and compositions for treating conditions associated with an abnormal inflammatory responses
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
SG10201909093XA (en) Mixed allergen compositions and methods for using the same
WO2018077944A3 (fr) 1,2,4-triazolones 4,5-annelées
WO2016004305A3 (fr) Inhibiteurs de la tyrosine kinase de bruton
MX2023003678A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
HK1206726A1 (en) Imidazotriazinone compounds
EP4667565A3 (fr) Procédés et compositions pour le traitement de la maladie de fabry
JOP20210230A1 (ar) صياغات صيدلانية
EP4653537A3 (fr) Rhodopsin-gentherapie zur regeneration des sehvermögens oder zur verhinderung der abnahme des sehvermögens
MY205028A (en) Protein for treatment of inflammatory diseases
WO2018033941A3 (fr) Compositions pharmaceutiques à base d'ibrutinib
MX2023003675A (es) Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos.
EP4438618A3 (fr) Compositions de cyclosporine et méthodes d'utilisation
WO2016205397A3 (fr) Administration spécifique de cible d'agents thérapeutiques
WO2017042577A8 (fr) Nouvelle thérapie
WO2019054808A3 (fr) Utilisation de peptides en tant qu'agent thérapeutique contre des maladies auto-immunes et des maladies osseuses
MX2025015454A (es) Formulaciones/composiciones que comprenden ibrutinib
WO2019054809A3 (fr) Utilisation de peptides en tant qu'agent thérapeutique contre des maladies auto-immunes et des maladies osseuses

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18857312

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3075607

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2020515231

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018332486

Country of ref document: AU

Date of ref document: 20180914

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018857312

Country of ref document: EP

Effective date: 20200415